ReviewCancer communications (London, England)2020
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.
Review in Cancer communications (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
- Integrated single-cell and bulk RNA-seq analysis reveals an NK-cell-related immune landscape and a prognostic signature for hepatocellular carcinoma.Discover oncology · 2026Article
- Using Immune Clusters for Classifying Heterogeneity of Immunity in Healthy Adults.Current medical science · 2026Article
- Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.European radiology · 2026Article
- Article
- Multi-omics and machine learning refine HCC molecular subtypes and prognosis based on liquid-liquid phase separation related genes.Scientific reports · 2025Article
- Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition.Journal of advanced research · 2025Article
- Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.Nature communications · 2025Article
- Deciphering riddles in molecular subtyping of bladder cancer.Asian journal of urology · 2025Review
- Intratumoral and peritumoral CT radiomics in predicting anaplastic lymphoma kinase mutations and survival in patients with lung adenocarcinoma: a multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The Predictive Significance of Interleukin-2 Receptor in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- CGR11 promotes hepatocellular carcinoma progression by regulating autophagy through the PI3K/AKT pathway.Frontiers in cell and developmental biology · 2025Article
- Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy.Journal of inflammation research · 2025Article
- Integrative Spatial Transcriptomics and Experimental Validation Reveal UBC-Mediated EMT Associated with Immune Evasion in Hepatocellular Carcinoma.ImmunoTargets and therapy · 2025Article
- Review
- IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma.Discover oncology · 2024Article
- Generalizable transcriptome-based tumor malignant level evaluation and molecular subtyping towards precision oncology.Journal of translational medicine · 2024Article
- Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.PLoS computational biology · 2024Article
- Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer.Journal of translational medicine · 2024Review
- Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal digestive tumors. Treatment for this disease has been constraint by heterogeneity of this group of tumors, which has greatly limited the progress in personalized therapy. Although existing studies have revealed the genetic and epigenetic blueprints that drive HCCs, many of the molecular mechanisms that lead to HCCs remain elusive. Recent advances in techniques for studying functional genomics, such as genome sequencing and transcriptomic analyses, have led to the discovery of molecular mechanisms that participate in the initiation and evolution of HCC. Integrative multi-omics analyses have identified several molecular subtypes of HCC associated with specific molecular characteristics and clinical outcomes. Deciphering similar molecular features among highly heterogeneous HCC patients is a prerequisite to implementation of personalized therapeutics. This review summarizes the current research progresses in precision therapy on the backbone of molecular subtypes of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.